Solutions: Extend trial to 6 months before concluding inefficacy (some benefits take longer), increase dosing within safe ranges if using lower end, switch peptides (try Cerebrolysin if using BPC-157, or vice versa), add comprehensive eye exam to rule out progression versus peptide failure, consider peptides preventing worsening rather than producing improvement, discontinue if truly no benefit after 6 months rigorous trial
[4] NAD + and SAM changes are not automatically harmful, and they should not be interpreted as toxicological findings by themselves
Otherwise, feel free to contact us (we may even add your question to the list)
Important Note on the Evidence Base To our knowledge, no peer-reviewed clinical or preclinical study has tested the specific BPC-157 + TB-500 combination at the amounts or ratios sold in this product
Concentration (start) Volume (start) = Concentration (final) Volume (final) Purity & Documentation Data Sheet (295 KB) SDS (254 KB) English - EN (254 KB) Franais - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Espaol - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB) Handling Instructions (2659 KB) References [1]